Researchers at Memorial Sloan-Kettering Cancer Center and Eureka Therapeutics have shown the anti-cancer efficacy of ESKM in resistant human Ph+ ALL.
ESKM is a human IgG1 T-cell receptor mimic monoclonal antibody directed to a 9 amino acid sequence of WT1 in the context of cell surface HLA-A*02. The antibody is therapeutically effective, alone and in combination with tyrosine kinase inhibitors (TKIs,) against Philadelphia chromosome positive acute leukemia in murine models, including a leukemia with the most common, pan-TKI, gate keeper resistance mutation, T315I. In combination with tyrosine kinase inhibitors, ESKM can result in cure of Ph+ ALL in murine models.
The antibody was developed under a collaborative effort between Eureka Therapeutics and Memorial Sloan-Kettering Cancer Center.